Akzo Nobel India Limited (BOM:500710)

Marinus Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	40,500	40,912	39,616	38,021	31,486	24,214
Other Revenue	3	3	3	-	-	-
Revenue	40,503	40,915	39,619	38,021	31,486	24,214
Revenue Growth (YoY)	1.29%	3.27%	4.20%	20.76%	30.03%	-9.03%
Cost of Revenue	23,550	23,599	22,625	23,259	19,054	13,478
Gross Profit	16,953	17,316	16,994	14,762	12,432	10,736
Selling, General & Admin	4,654	4,563	4,501	3,953	3,212	3,080
Other Operating Expenses	6,218	6,328	6,154	5,530	4,844	4,155
Operating Expenses	11,731	11,785	11,478	10,308	8,815	7,990
Operating Income	5,222	5,531	5,516	4,454	3,617	2,746
Interest Expense	-93	-91	-97	-99	-90	-82
Interest & Investment Income	262	262	353	255	194	199
Currency Exchange Gain (Loss)	-	-	-5	-17	-31	-67
Other Non Operating Income (Expenses)	-14	-7	-28	-31	-38	-5
EBT Excluding Unusual Items	5,377	5,695	5,739	4,562	3,652	2,791
Gain (Loss) on Sale of Investments	11	11	-	-	7	-
Gain (Loss) on Sale of Assets	-7	-7	-11	-11	-20	-26
Other Unusual Items	-	-	2	8	29	17
Pretax Income	5,381	5,699	5,730	4,559	3,668	2,782
Income Tax Expense	1,322	1,404	1,464	1,208	767	706
Earnings From Continuing Operations	4,059	4,295	4,266	3,351	2,901	2,076
Net Income	4,059	4,295	4,266	3,351	2,901	2,076
Net Income to Common	4,059	4,295	4,266	3,351	2,901	2,076
Net Income Growth	-5.89%	0.68%	27.30%	15.51%	39.74%	-12.55%
Shares Outstanding (Basic)	46	46	46	46	46	46
Shares Outstanding (Diluted)	46	46	46	46	46	46
Shares Change (YoY)	0.03%	-	-	-	-	-
EPS (Basic)	89.12	94.31	93.68	73.58	63.70	45.59
EPS (Diluted)	89.12	94.31	93.68	73.58	63.70	45.59
EPS Growth	-5.92%	0.68%	27.31%	15.51%	39.74%	-12.55%
Free Cash Flow	-	2,045	3,670	3,819	580	2,551
Free Cash Flow Per Share	-	44.91	80.59	83.86	12.74	56.02
Dividend Per Share	-	100.000	75.000	65.000	75.000	50.000
Dividend Growth	-	33.33%	15.38%	-13.33%	50.00%	257.14%
Gross Margin	41.86%	42.32%	42.89%	38.83%	39.48%	44.34%
Operating Margin	12.89%	13.52%	13.92%	11.71%	11.49%	11.34%
Profit Margin	10.02%	10.50%	10.77%	8.81%	9.21%	8.57%
Free Cash Flow Margin	-	5.00%	9.26%	10.04%	1.84%	10.54%
EBITDA	5,946	6,237	6,151	5,088	4,190	3,330
EBITDA Margin	14.68%	15.24%	15.53%	13.38%	13.31%	13.75%
D&A For EBITDA	723.75	706	635	634	573	584
EBIT	5,222	5,531	5,516	4,454	3,617	2,746
EBIT Margin	12.89%	13.52%	13.92%	11.71%	11.49%	11.34%
Effective Tax Rate	24.57%	24.64%	25.55%	26.50%	20.91%	25.38%
Revenue as Reported	40,769	41,188	39,974	38,295	31,713	24,446
Advertising Expenses	-	1,152	1,192	916	549	537

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.